Skip to Main Content

Paper Details

Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.
NPJ Breast Cancer
15
2021
BRCA, BRCA1, BRCA1 or BRCA2 mutations, BRCA2 mutations, BRCAmut, BROCA, Cancer, Cisplatin, Germline, PARP, Patients, Rucaparib, TNBC, cisplatin, patients, rucaparib, triple-negative breast cancer, triple-negative or BRCA mutated breast cancer
Author NameAffiliation
Tom WalshUniversity of Washington
Tom WalshUniversity of Washington
Cynthia X MaSiteman Cancer Center, Washington University
Mary-Claire KingUniversity of Washington
Mary-Claire KingUniversity of Washington
Susan M PerkinsIndiana University School of Medicine
  • 1 - 6

Datasets

Release 1.2